Navigation Links
Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
Date:5/18/2009

yne, PA. The mezzanine debt would have matured February 28, 2010. In addition, the facility carries an annual interest rate of 14% and would have required the issuance of a substantial number of warrants beginning June 1, 2009, if it were not terminated before that date.

"This transaction has the added benefit of reducing interest expense, fees and amortization expense by $12 million for the remainder of 2009 which greatly enhances Clarient's potential for net earnings by year end," Andrews concluded.

The purchase price of the Clarient Series A convertible preferred stock was $7.60 per share, which equates to an effective purchase price of $1.90 per share of underlying common stock or approximately market price at the date the financing was agreed upon. Under terms of the private placement, Oak may convert at any time one convertible preferred share into four shares of Clarient common stock. After one year, preferred shares, which do not accrue dividends, convert automatically into common shares if Clarient shares trade above $4.75 per share for 20 days of a 30 consecutive trading-day period. After four years, Clarient may redeem any unconverted preferred shares at $7.60 per share plus any undeclared but unpaid dividends.

Upon mutual agreement after the closing of the second tranche, Oak may purchase up to an additional $10 million of Clarient preferred shares, providing the company access to capital for strategic opportunities that would accelerate the company's growth.

The private placement gives Oak effective control of approximately 21% of Clarient's outstanding shares and reduces Safeguard's position to approximately 47% from nearly 62% at December 31, 2008. With certain exceptions, preferred shares will be voted with common shares on an as-converted basis. Safeguard first took an ownership stake in Clarient in 1996, increasing its position over time.

About Clarient
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
2. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
3. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
4. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
5. Jim Agnello to Resign as Clarient Chief Financial Officer
6. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
7. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
8. Clarient to Commercialize Novel Breast Cancer Profile
9. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
10. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
11. NovImmune Completes CHF 62.5 (USD 54.8) Million Equity Financing to Move Portfolio Forward and Reacquire Product Rights to Lead Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 Synthetic Biologics, Inc. (NYSE ... and treatment of serious infectious diseases, announced today that ... Annual OneMedForum New York Conference on Thursday, June 27, ... City . Mr. Riley is scheduled to present at ... Synthetic Biologics, presentation can be accessed by logging onto the ...
(Date:6/19/2013)...   NineSigma , Inc., of Cleveland ... launch, NineSights.com is now the innovation engine ... worldwide community of innovators. From technology developers, ... NineSights stands out for its large community of innovators ... disciplines, all vetted by NineSigma. The community is free ...
(Date:6/19/2013)... Biotechnology industry pioneer Amgen (NASDAQ: AMGN ... Systems  and enterprise application software leader SAP AG ... week entitled "No Account Left Behind!  Learn ... Keep Its Account Reconciliations in Good Shape ."    ... webinar, geared at finance, accounting, audit and compliance managers in ...
(Date:6/19/2013)... 2013 India’s vast and growing ... be worth up to a billion dollars per ... government is taking serious action to better regulate ... This presentation will examine:, ,     Recent ...     Immediate and long term impacts ,     Foreseeable ...
Breaking Biology Technology:Synthetic Biologics to Present at OneMedForum New York 2013 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 2Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 4
... -. Actavis Group, the,international generic pharmaceuticals company, has ... Food & Drug,Administration. Distribution of the product will ... equivalent to Pfizer,s,Camptosar(R) will be available in 40 ... and is,used in the treatment of patients with ...
... CryoCath,s Cryoablation System, SAN DIEGO, Feb. 28 ... focused on the treatment of cardiac,arrhythmias, announced today ... the,United States International Trade Commission (ITC) alleging that ... by infringing on,several CryoCor patents with its cryoablation ...
... Johnson, Jr. Resigns as President and Chief Executive ... Opportunities, HAYWARD, Calif., Feb. 28 Kosan ... Robert G. Johnson, Jr.,M.D., Ph.D., has resigned as ... Kosan,s Board of Directors. Helen S. Kim, who ...
Cached Biology Technology:Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product 2CryoCor Requests International Trade Commission Investigation Into CryoCath for Patent Infringement 2CryoCor Requests International Trade Commission Investigation Into CryoCath for Patent Infringement 3Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 2Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 3Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 4Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 5Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 6Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 7Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 8
(Date:6/18/2013)... Department,s National Renewable Energy Laboratory (NREL), and the ... describing a novel cellulose-degrading enzyme from a marine ... as the gribble. , Gribbles are biologically ... to produce their own enzymes instead of using ... eat. New biomass-degrading enzymes from novel sources such ...
(Date:6/18/2013)... The National Institutes of Health has awarded $12.7 ... a selection of pharmaceutical industry compounds to explore ... including Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. ... Uses for Existing Molecules, is led by the ... funded by the NIH Common Fund. , The ...
(Date:6/18/2013)... chemical modification of DNA and this modification can ... sequence. Until now, scientists believed that this epigenetic ... Today, a team of researchers from the University ... Louis-Jeantet Professor at the Faculty of Medicine, reveals ... that DNA methylation may play both a passive ...
Breaking Biology News(10 mins):Novel enzyme from tiny gribble could prove a boon for biofuels research 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4The secret of DNA methylation 2
... us to spot prey, vision keeps many animals, including humans, ... why is it easier for us to spot movement of ... other things? The complexity of the neural network that supports ... technology and support from the National Science Foundation, Claire Wyart ...
... Calif., November 1, 2010 One of the many advantages ... which in turn supports a healthy heart. Fat tissue is ... it,s also an active secretory organ that normally produces high ... the hearts of healthy people has long been a mystery, ...
... developing a cost-effective electronic monitoring system that will enable ... by allowing users to track water-quality data from these ... National Science Foundation (NSF) grant. "Our goal is ... conditions in the Chesapeake Bay, the sounds of North ...
Cached Biology News:The zebrafish's neural circuit prevents it from biting off more than it can chew 2Study finds fat hormone's long-sought link to heart protection 2Researchers developing real-time electronic monitoring for coastal waters 2
...
... Solid phase reagent ... purification; Easy & unique ... Compatible with detergents and ... & recover non-envelop viruses ...
Synaptic Vesicle I Sampler Kit 10g each...
Mouse monoclonal [3A7.A11] to Thymidylate Synthase ( Abpromise for all tested applications). entrezGeneID: 7298 SwissProtID: P04818...
Biology Products: